PBHPrestige Consumer Healthcare Inc.
Price
-23%1YEnd-of-day closes, not the intraday tick.
Mostly good, one thing to check: growth
Quality strong, no red flags, undemanding price, growth fading, the market undecided.
We formed as a Delaware corporation in 1996 and are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter (“OTC”) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets.
In the company’s own words · 10-K filed May 14, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Prestige Consumer Healthcare Inc. (PBH) reported revenue of $266M in Q1 2027 (quarter ended Jun 30, 2026), up 6.5% from the same quarter a year earlier. That came with a gross margin of 51% and net income of $29M (11% of revenue). For the full year FY2026, revenue was $1.09B (−4.3% year on year) and net income $190M. Its largest product in Q1 2027 was Womens Health at $47M, 20.4% of the disclosed total, just ahead of Gastrointestinal at 20.4%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 14, 2026On August 10, 2026, Jeffrey Zerillo notified Prestige Consumer Healthcare Inc. (the “Company”) of his decision to retire from his position as Senior Vice President, Operations and from all other positions he holds with the Company, effective August 14, 2026.Director or officer change · Form 8-K
- Aug 6, 2026Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results.Earnings release · press release
- Jul 15, 2026On July 15, 2026, Prestige Brands, Inc. (“Prestige Brands”), a wholly owned subsidiary of Prestige Consumer Healthcare Inc. (the “Company”), issued $400.0 million aggregate principal amount of 6.250% senior notes due 2034 (the “2026 Notes” or “notes”) pursuant to an Indenture, dated July 15, 2026 (the “Indenture”) …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $231.6MThe company’s own SEC segment disclosure.
- Womens Health$47.2M20%
- Gastrointestinal$47.1M20%
- Dermatologicals$30.6M13%
- Eye And Ear Care$28.3M12%
- Pain Relief$26.2M11%
- Oral Care$18.5M8%
- Other (3)$33.6M14%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #11 of 41 by RyuScore